

# Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

NCT07090226

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Not Applicable
<b>Sponsor</b>	Boston University
<b>Enrollment</b>	65 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Scleroderma (SSc) participants must have been diagnosed with SSc as defined by the American College of Rheumatology within the past 2-5 years AND fulfill criteria for diffuse cutaneous SSc according to LeRoy classification
- Healthy controls must be free of SSc or other autoimmune disease and have no known skin pathology

### Exclusion (6)

- Diagnosis of skin malignancy within the previous 2 years, excluding adequately treated squamous cell skin cancer, basal cell carcinoma, and carcinoma in situ.
- Presence of wounds or skin rashes at the site of Spatial frequency domain imaging (SFDI) measurement or skin biopsy
- Presence of other co-morbid illnesses with an estimated median life expectancy  $\leq$  5 years.
- Subject has known allergy to lidocaine or has had a reaction to local anesthetics in the past will not provide skin biopsy samples at any time during the study.
- Subjects who, in the opinion of the investigator, are high-risk for small tissue calcification, or other conditions that may affect wound healing will not provide skin biopsy samples at any time during the study.

... and 1 more (see full listing online)

## Locations (1 total)

---

Shapiro Outpatient Rheumatology Clinic at Boston Medical Center, Boston, Massachusetts, United States